These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23698372)

  • 1. Cancer: Drug for an 'undruggable' protein.
    Baker NM; Der CJ
    Nature; 2013 May; 497(7451):577-8. PubMed ID: 23698372
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticancer drugs: A new approach for blocking KRAS.
    Tse MT
    Nat Rev Drug Discov; 2013 Jul; 12(7):506. PubMed ID: 23787956
    [No Abstract]   [Full Text] [Related]  

  • 3. Fixing a hole where the Ras gets in.
    Iwig JS; Kuriyan J
    Cell; 2013 Jun; 153(6):1191-3. PubMed ID: 23746837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
    Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
    Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RAS: The Elusive Prize.
    Bates SE
    Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
    Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
    J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
    Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K
    Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of inhibition of ras-p21 signal transduction by peptides from GTPase activating protein (GAP) and the son-of sevenless (SOS) ras-specific guanine nucleotide exchange protein.
    Chie L; Chung D; Pincus MR
    Protein J; 2005 May; 24(4):253-8. PubMed ID: 16283548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras hitchhikes on PDE6δ.
    Philips MR
    Nat Cell Biol; 2012 Feb; 14(2):128-9. PubMed ID: 22298042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ras oncogene: a novel approach to antineoplastic therapy.
    Scharovsky OG; Rozados VR; Gervasoni SI; Matar P
    J Biomed Sci; 2000; 7(4):292-8. PubMed ID: 10895051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer: The Ras renaissance.
    Ledford H
    Nature; 2015 Apr; 520(7547):278-80. PubMed ID: 25877186
    [No Abstract]   [Full Text] [Related]  

  • 12. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoskeletal tumor suppressors that block oncogenic RAS signaling.
    Maruta H; He H; Tikoo A; Nur-e-Kamal M
    Ann N Y Acad Sci; 1999; 886():48-57. PubMed ID: 10667202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based development of PDEδ inhibitors.
    Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
    Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.
    Jasinski P; Zwolak P; Terai K; Dudek AZ
    Transl Res; 2008 Nov; 152(5):203-12. PubMed ID: 19010291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?
    Frett B; Wang Y; Li HY
    ChemMedChem; 2013 Oct; 8(10):1620-2. PubMed ID: 23939923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular perspective: the ras oncogene.
    Goodsell DS
    Stem Cells; 1999; 17(4):235-6. PubMed ID: 10437988
    [No Abstract]   [Full Text] [Related]  

  • 19. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor.
    Shalom-Feuerstein R; Lindenboim L; Stein R; Cox AD; Kloog Y
    Cell Death Differ; 2004 Feb; 11(2):244-7. PubMed ID: 14576773
    [No Abstract]   [Full Text] [Related]  

  • 20. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
    Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
    BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.